Eli Lilly EVP buys 1,000 shares at $647.36 on Aug. 13, 2025.

Eli Lilly & Company reports that Van Naarden Jacob, Executive Vice President and President of Lilly Oncology, has made a recent investment in the company. On August 13, 2025, Jacob acquired 1000 shares at a price of $647.36 per share.

Title: Eli Lilly & Co. Reports Insider Investment by Van Naarden Jacob

Eli Lilly & Company (NYSE: LLY) has disclosed that Van Naarden Jacob, Executive Vice President and President of Lilly Oncology, made a significant investment in the company. According to a recent SEC Form 4 filing [1], Jacob acquired 1000 shares of Eli Lilly's common stock on August 13, 2025, at a price of $647.36 per share. This purchase brought his total beneficial ownership to 20,561.985 shares.

This investment comes amidst a period of strategic growth and market expansion for Eli Lilly. The company has recently launched its best-selling diabetes drug, Mounjaro, in a new injector pen format in India, intensifying its competition with Novo Nordisk in the GLP-1 market [2]. Despite the strong financial performance reported in the second quarter of 2025, investor sentiment was affected by disappointing clinical trial data for Orforglipron, a weight loss drug candidate [3].

Eli Lilly faces ongoing challenges, including a lawsuit from the Texas Attorney General accusing the company of bribing healthcare providers to prescribe its medications, particularly GLP-1 drugs Mounjaro and Zepbound [3]. Despite these challenges, analysts maintain varying perspectives on the company's future, with some retaining positive outlooks due to the growth potential in the GLP-1 market [3].

References
1. [SEC Form 4](https://www.stocktitan.net/sec-filings/LLY/form-4-eli-lilly-co-insider-trading-activity-b52731b8b048.html)
2. [Eli Lilly Launches Mounjaro in India](https://finance.yahoo.com/news/eli-lilly-fires-glp-1-174856833.html)
3. [Guggenheim Lowers Price Target on Eli Lilly](https://www.investing.com/news/analyst-ratings/guggenheim-lowers-eli-lilly-stock-price-target-on-glp1-market-uncertainty-93CH-4188209)